ClinicalTrials.gg
RecruitingNCT06858332STaRTUpdated Nov 13, 2026

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

An observational study in Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals. Recruiting at 20 sites in Russia. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,382
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Atherosclerosis by Novartis — 4 open to participants now, 10 under way, 3 of them phase 3. Atherosclerosis · Novartis.

Started
2025
with 6 others
Observational
8 of 27
2 open now
Registered
20th of 27
by date

Among the 27 studies in Atherosclerosis by Novartis, this one is one of 7 that started in 2025, is one of 8 observational ones, and was the 20th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

4 of the 27 studies in Atherosclerosis by Novartis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Atherosclerosis by Novartis, or all of them as a file.
02

Study summary

This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.

Read the detailed description

This study will consist of several phases (consecutive stages):

Phase I: a cross-sectional study of Lp(a) level with ASCVD patients

Phase II:

  • A non-interventional, prospective, cohort study with the phase I patients
  • A cross-sectional study of Lp(a) levels with relatives of phase I patients
  • A non-interventional, prospective, cohort study with patients' relatives
03

Conditions studied

  • Atherosclerotic Cardiovascular Disease

Keywords

  • lipoprotein(a),
  • ASCVD,
  • cardiovascular disease,
  • CVD
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with the history of atherosclerotic cardiovascular disease (ASCVD). First-degree relatives of the ASCVD patient (patient's parents and children) with Lp(a) ≥125 nmol/L

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written (signed and dated).
  2. Males and females aged ≥18 years.
  3. Presence of one of the following ASCVDs for at least 3 months within the 2 years prior to signing the informed consent to participate in this study:

    • history of MI;
    • history of IS and/or ;
    • IHD confirmed by coronary angiography (stenosis ≥50%);
    • any revascularization surgery (emergency or planned), including CABG, PCI, carotid endarterectomy or carotid/intracranial stenting;
    • peripheral artery disease (intermittent claudication with ankle-brachial index ≤0.90 and/or lower limb amputation or revascularization in case of lower limb ischemia).

Exclusion criteria

Exclusion Criteria:

  1. Acute infectious and inflammatory diseases, such as COVID-19, in the month leading up to the Screening visit.
  2. Lp(a)-lowering therapy/methods (Lp(a) apheresis with PCSK9 inhibitors, inclisiran prior to the Screening visit) in the medical history before the Screening visit.
  3. Participation in any interventional clinical study with or marketed medicinal products at the time of enrollment.
  4. Participation in other real-world clinical studies.
  5. Stages 4 and 5 of chronic kidney disease ( CKD-EPI \<30 mL/min/1.73 m2) and/or hepatic disease (total : 2 × ).

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,382 participants (estimated)
Patient registry
No

Groups and cohorts

  • ASCVD patients

    Patients aged 18 and above with a history of ASCVD including peripheral arterial revascularization

    Drug: Atorvastatin · Drug: Simvastatin · Drug: Rozuvastatin · Drug: Ezetimibe · Drug: Niacin · Drug: Ciprofibrate · Drug: Fenofibrate · Drug: Bezafibrate · Drug: Evolocumab · Drug: Alirocumab · Drug: Inclisiran

  • Relatives of the ASCVD patients

    A first-degree relative of the ASCVD patient (patient's parents and children) with Lp(a) ≥125 nmol/L.

    Drug: Atorvastatin · Drug: Simvastatin · Drug: Rozuvastatin · Drug: Ezetimibe · Drug: Niacin · Drug: Ciprofibrate · Drug: Fenofibrate · Drug: Bezafibrate · Drug: Evolocumab · Drug: Alirocumab · Drug: Inclisiran

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients (%) with Lp(a) ≥125 nmol/L

    Percentage of patients (%) with Lp(a) ≥125 nmol/L at baseline

    Time frame: Baseline

  2. The difference in the number of patients with cardiovascular events (%) between the groups

    The difference in the number of patients (%) with new cardiovascular events between the groups of patients with elevated Lp(a) ≥125 nmol/L and Lp(a) \<125 nmol/L

    Time frame: 24 months

Secondary outcomes

  1. Percentage of patients (%) with at least one CVD, and ASCVD number in different subgroups stratified by Lp(a) level

    Percentage of patients (%) with at least one CVD by Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L \*CVD - Cardiovascular disease; ASCVD - Atherosclerotic cardiovascular disease

    Time frame: Baseline

  2. Percentage of ASCVD patients (%) in accordance with the Lp(a) level

    Percentage of ASCVD patients (%) by Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  3. Age of patients at the time of the first ASCVD in different subgroups in accordance with the Lp(a) level

    Age of patients at the time of the first ASCVD in different subgroups by Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  4. Percentage of patients (%) with disability groups I, II, and III in different subgroups stratified by the Lp(a) level

    Percentage of patients (%) with disability groups I, II, and III in different subgroups stratified by the Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  5. Age of assignment of any disability group in different subgroups by the Lp(a) level

    Age of assignment of any disability group in different subgroups by the Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  6. Duration of temporary incapacity (sick leave) following the onset of CVE in different subgroups based on Lp(a) level

    Duration of temporary incapacity (sick leave) following the onset of CVE (cardiovascular event) in different subgroups based on Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  7. Percentage of patients (%) without an official disability status who had to completely stop working after developing CVE in different subgroups based on Lp(a) level

    Percentage of patients (%) without an official disability status who had to completely stop working after developing CVE (cardiovascular event) in different subgroups based on Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  8. Lp(a) distribution level by a ASCVD type

    Percentage of patients with peripheral artery disease (PAD), ischemic stroke (IS), ischemic heart disease by the Lp(a) level\* \*≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  9. Percentage (%) of ASCVD patients with elevated Lp(a) levels by gender and age (20-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90 years)

    Percentage (%) of ASCVD patients with elevated Lp(a) levels by gender and age (20-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90 years)

    Time frame: Baseline

  10. Percentage of patients (%) with hemodynamically significant coronary atherosclerosis (stenosis ≥50%) in different subgroups by the Lp(a) level

    Percentage of patients (%) with hemodynamically significant coronary atherosclerosis (stenosis ≥50%) in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  11. Percentage of ASCVD patients (%) with elevated Lp(a) levels in groups stratified by the number of coronary arteries with hemodynamically significant stenosis in patients with relevant available data

    Percentage of ASCVD patients (%) with elevated Lp(a) levels in groups stratified by the number of coronary arteries with hemodynamically significant stenosis in patients with relevant available data

    Time frame: Baseline

  12. Percentage (%) of ASCVD patients with an elevated Lp(a) level classified depending on the presence of multifocal atherosclerosis, ischemic heart disease, and peripheral artery disease

    Percentage (%) of ASCVD patients with an elevated Lp(a) level classified depending on the presence of multifocal atherosclerosis, ischemic heart disease, and peripheral artery disease

    Time frame: Baseline

  13. Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different numbers of MI events

    Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different numbers of myocardial infarction (MI) events

    Time frame: Baseline

  14. Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different numbers of IS and TIA events

    Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different numbers of ischemic stroke (IS) and transient ischemic attack (TIA) events

    Time frame: Baseline

  15. Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different types of hospitalization (planned/emergency)

    Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different types of hospitalization (planned/emergency)

    Time frame: Baseline

  16. Percentage (%) of ASCVD patients with elevated Lp(a) levels classified by the first cardiovascular event (CVE)

    Percentage (%) of ASCVD patients with elevated Lp(a) levels classified by the first CVE (any of the following: myocardial infarction, ischemic stroke, transient ischemic attack, percutaneous coronary intervention, etc.)

    Time frame: Baseline

  17. Percentage of ASCVD patients (%) with elevated Lp(a) levels by the PCI number (planned/emergency)

    Percentage of ASCVD patients (%) with elevated Lp(a) levels by the percutaneous coronary intervention (PCI) number (planned/emergency)

    Time frame: Baseline

  18. Percentage of patients (%) with the first CVE (MI or IS) (before the Screening visit) in different subgroups by the Lp(a) level

    Percentage of patients (%) with the first CVE (MI or IS) (before the Screening visit) in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  19. Percentage of patients (%) with several CVEs (MI or IS) (before the Screening visit) in different subgroups by the Lp(a) level

    Percentage of patients (%) with several CVEs (MI or IS) (before the Screening visit) in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  20. Number of recurrent CVEs in different subgroups by the Lp(a) level

    Number of recurrent CVEs in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  21. Percentage of patients (%) with unstable angina, manifestations of TIA, PCI, and CABG in medical history (before the Screening visit) in different subgroups by the Lp(a) level

    Percentage of patients (%) with unstable angina, manifestations of transient ischemic attack (TIA), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) in medical history (before the Screening visit) in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  22. Percentage of patients (%) with multiple CVE, such as unstable angina, TIA, PCI, and CABG (before or after the index/screening visit), in different subgroups based on Lp(a) level

    Percentage of patients (%) with multiple CVE, such as unstable angina, transient ischemic attack (TIA), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) (before or after the index/screening visit), in different subgroups based on Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L

    Time frame: Baseline

  23. Percentage of patients (%) with severe CVE (MI, IS) (after the index/screening visit) based on the Lp(a) level in different subgroups

    Percentage of patients (%) with severe CVE (MI, IS) based on the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months

    Time frame: 3, 9, 12, 18, and 24 months

  24. Number of patients with recurrent CVEs (more than one event during the follow-up period) and the mean number of recurrent complications in the post-index visit period

    Number of patients with recurrent CVEs (more than one event during the follow-up period) and the mean number of recurrent complications at 3, 9, 12, 18, and 24 months

    Time frame: 3, 9, 12, 18, and 24 months

  25. Percentage of patients (%) with cardiovascular deaths after the index/screening visit in different subgroups by the Lp(a) level

    Percentage of patients (%) with cardiovascular deaths in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months

    Time frame: 3, 9, 12, 18, and 24 months

  26. Percentage of patients who died after the index/screening visit in different subgroups by the Lp(a) level

    Percentage of patients who died in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months

    Time frame: 3, 9, 12, 18, and 24 months

  27. Percentage of patients (%) who needed emergency medical care or visited a medical facility during the period following the index/screening visit in different subgroups by the Lp(a) level

    Percentage of patients (%) who needed emergency medical care or visited a medical facility in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months

    Time frame: 3, 9, 12, 18, and 24 months

  28. Number of emergency visits or visits to a medical facility following the index/screening visit in various subgroups by the Lp(a) level

    Number of emergency visits or visits to a medical facility in various subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months

    Time frame: 3, 9, 12, 18, and 24 months

  29. Percentage of ASCVD patients (%) who achieved the target LDL-C level with the current lipid-lowering therapy

    Percentage of ASCVD patients (%) who achieved the target LDL-C level with the current lipid-lowering therapy

    Time frame: 3, 9, 12, 18, and 24 months

  30. Percentage of ASCVD patients (%) receiving lipid-lowering therapy, who experienced a change in Lp(a) levels

    Percentage of ASCVD patients (%) receiving lipid-lowering therapy, who experienced a change in Lp(a) levels

    Time frame: 3, 9, 12, 18, and 24 months

  31. Number of first-degree relatives (%) of patients with Lp(a) ≥125 nmol/

    Number of first-degree relatives (%) of patients with Lp(a) ≥125 nmol/L

    Time frame: Baseline

  32. Difference between groups in the number of relatives (%) with CVD complications during the 2-year observation period

    The difference in the number of relatives (%) with new cardiovascular events between the groups of patients with elevated Lp(a) ≥125 nmol/L and Lp(a) \<125 nmol/L

    Time frame: 24 months

07

Study locations

20 of 20 sites recruiting
  • Novartis Investigative Site
    Chelyabinsk, 454048, Russia
    Recruiting
  • Novartis Investigative Site
    Chelyabinsk, 454076, Russia
    Recruiting
  • Novartis Investigative Site
    Kaluga, 248000, Russia
    Recruiting
  • Novartis Investigative Site
    Kemerovo, 650002, Russia
    Recruiting
  • Novartis Investigative Site
    Krasnoyarsk, 680022, Russia
    Recruiting
  • Novartis Investigative Site
    Moscow, 119881, Russia
    Recruiting
  • Novartis Investigative Site
    Moscow, 121552, Russia
    Recruiting
  • Novartis Investigative Site
    Moscow, 125284, Russia
    Recruiting
  • Novartis Investigative Site
    Omsk, 644024, Russia
    Recruiting
  • Novartis Investigative Site
    Perm, 614002, Russia
    Recruiting
  • Novartis Investigative Site
    Ryazan, 390039, Russia
    Recruiting
  • Novartis Investigative Site
    Surgut, 628403, Russia
    Recruiting
  • Novartis Investigative Site
    Tomsk, 634009, Russia
    Recruiting
  • Novartis Investigative Site
    Tyumen, 625026, Russia
    Recruiting
  • Novartis Investigative Site
    Vladimir, 600020, Russia
    Recruiting
  • Novartis Investigative Site
    Vladivostok, 690000, Russia
    Recruiting
  • Novartis Investigative Site
    Voronezh, 394018, Russia
    Recruiting
  • Novartis Investigative Site
    Yakutsk, 677013, Russia
    Recruiting
  • Novartis Investigative Site
    Yekaterinburg, 620137, Russia
    Recruiting
  • Novartis Investigative Site
    Yekaterinburg, 620144, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.

Of 170 observational studies under Atherosclerosis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 153. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Mar 5, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06858332
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Apr 15, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion